![[Review] Autosomal Dominant Polycystic Kidney Disease](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/e5c772f073be33a83118f46a1ac91f13.webp)
[Review] Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) remains the most common hereditary cause of chronic kidney disease, imposing substantial morbidity, mortality, and healthcare costs worldwide. Recent advances in molecular genetics and high‑resolution imaging have sharpened diagnostic criteria and enabled more accurate risk stratification. Robust trial data now support early use of the vasopressin‑V2 antagonist tolvaptan in patients at high risk of rapid renal decline. Comprehensive care pathways that integrate screening for cyst infections, intracranial aneurysms, and polycystic liver disease are essential for optimal patient outcomes.
![[Comment] Safeguarding Genomic Integrity in Pluripotent Stem-Cell Therapies](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/fba52b2aab9c591bf0e059f57acce9ea.webp)
[Comment] Safeguarding Genomic Integrity in Pluripotent Stem-Cell Therapies
Human pluripotent stem cells (hPSCs) are emerging as a transformative platform for Parkinson’s disease, with recent phase I/II trials showing successful engraftment of hESC‑ and iPSC‑derived dopaminergic neurons. Yet extensive data reveal that cultured hPSCs frequently acquire recurrent genetic lesions—most...
FDA Approves Next-Generation CardioMEMS Reader for Heart Failure Monitoring
Abbott received FDA approval for its next‑generation CardioMEMS HERO reader, a pulmonary artery pressure device for heart‑failure patients. The HERO unit is 60% lighter than earlier readers and incorporates built‑in Wi‑Fi and cellular connectivity, allowing measurements anywhere. The upgrade builds on...
The Science of Controlling Drug Release in Implants with Ultrasonic Spray Coating
Ultrasonic spray coating is emerging as a core engineering discipline for drug‑eluting implants, with parameters such as drug‑to‑polymer ratio, nitrogen carrier‑gas flow, nozzle height, and spray power dictating coating thickness, profile, and elution behavior. The article explains how variations in...
Promoters and Enhancers: Tool Catches Gene-Controlling DNA Sequences Doing Each Other's Jobs
Researchers at Cornell’s Weill Institute introduced QUASARR‑seq, a high‑throughput assay that measures promoter and enhancer activity simultaneously. The study found that most human regulatory elements can function as both promoters and enhancers, following a unified regulatory logic. A bidirectional feedback...
Size-Shifting Nanoparticles Successfully Deliver mRNA Medicine to the Pancreas
Researchers have engineered size‑shifting lipid nanoparticles that grow from ~100 nm to >300 nm after intraperitoneal injection, exploiting a capsule‑filter mechanism that blocks entry into the liver and spleen while allowing passage to the pancreas. The enlarged particles deliver mRNA payloads—including CRISPR‑Cas9...
Lilly Launches LillyPod NVIDIA DGX SuperPOD for Genomics and Drug Discovery AI
Eli Lilly unveiled LillyPod, a DGX SuperPOD built with 1,016 NVIDIA Blackwell Ultra GPUs delivering more than 9,000 petaflops of AI performance. The system powers genomics, protein‑diffusion, small‑molecule graph neural networks and foundation models, allowing billions of in‑silico experiments. Constructed...
Drug Trials Snapshot: HYRNUO
Bayer's HYRNUO (sevabertinib) received accelerated FDA approval on November 19, 2025 for adult patients with HER2‑mutated, non‑squamous non‑small cell lung cancer who have progressed after prior therapy. The approval is based on the single‑arm SOHO‑01 trial, which enrolled 122 patients across 78...
3D Bioprinted Corneal Implants May Ease Donor Tissue Shortage
Precise Bio successfully implanted PB-001, the world’s first 3D‑bioprinted, cell‑based corneal graft, in a legally blind patient during a phase‑1 trial. The implant combines human endothelial cells with a transparent collagen scaffold, replicating the properties of donor tissue. By using...
Cure Parkinson’s Expands Its Research Committee and Welcomes New Interns
Cure Parkinson’s has expanded its Research Committee by adding eight new members from leading UK and European institutions, spanning neurology, bioinformatics, pharmacology and more. The charity also welcomed three early‑career researchers as interns, extending the programme beyond the UK to...
Omics in Orlando Day 2: A Video Report From AGBT
The AGBT Day 2 video recap features Julianna LeMieux and Kevin Davies highlighting the meeting’s headline announcements. Vizgen unveiled a spatial‑omics platform aimed at organoid research, while Illumina introduced the TruPath Genome product, formerly known as Constellation mapped reads. Bruker launched...
NHS "Isn't Delivering Equitable Care for Rare Diseases"
Genetic Alliance UK’s equity report warns the NHS is falling short for the 3.5 million Britons living with rare diseases. A quarter of patients wait three years for a diagnosis, only 5 % of conditions have approved treatments, and just 10 % of...
A New Antibody Treatment For Breast Cancer
A year-long trastuzumab emtansine (T‑DM1) regimen showed 98% three‑year invasive‑disease‑free survival in early‑stage HER2‑positive breast cancer, comparable to standard paclitaxel‑plus‑trastuzumab. The ATEMPT trial of nearly 500 patients found similar overall survival but markedly lower neuropathy and hair loss with T‑DM1,...
Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program
The FDA granted accelerated approval to Boehringer Ingelheim’s oral HER2 kinase inhibitor Hernexeos six weeks after the company filed its application, marking the second approval under the new Commissioner’s National Priority Voucher (CNPV) program. The decision expands Hernexeos use to...
Promatix EGFR×EphA2 Bispecific ADC Exerts Antitumor Activity
Today’s brief highlights four pre‑clinical advances: Paratus Sciences unveiled PS‑1001, a pan‑inflammasome blocker targeting IL‑1β and IL‑18 for hidradenitis suppurativa; researchers identified the SCAN circuit as a core pathway disrupted in Parkinson’s disease; RX‑10616 demonstrated enhanced radiotherapy response in head‑and‑neck...
Prospect Therapeutics Identifies New JAK1 and TYK2 Inhibitors
Prospect Therapeutics announced the identification of a new series of small‑molecule inhibitors targeting Janus kinase 1 (JAK1) and tyrosine kinase 2 (TYK2). The lead compounds demonstrate nanomolar potency and selectivity in biochemical assays and effectively suppress cytokine signaling in cellular...
Drug Trials Snapshots
The FDA’s Drug Trials Snapshots program publishes concise, consumer‑focused summaries of the demographic makeup and outcomes of pivotal clinical trials for newly approved drugs. Launched in 2015, the tool covers only New Molecular Entities and original biologics approved after that...
Ionis’ Olezarsen sNDA Secures the US FDA Priority Review for Severe Hypertriglyceridemia
Ionis Pharmaceuticals received FDA acceptance of its supplemental NDA for olezarsen and a priority‑review designation, with a PDUFA action date of June 30, 2026. The decision is backed by two Phase III CORE studies—CORE (n=617) and CORE2 (n=446)—that evaluated once‑monthly subcutaneous...
Drug Trials Snapshots: EXDENSUR
GSK’s depemokimab, marketed as EXDENSUR, received FDA approval on December 16, 2025 as a six‑month subcutaneous add‑on for severe eosinophilic asthma in patients aged 12 and older. Approval was based on two 52‑week, double‑blind, placebo‑controlled trials (SWIFT‑1 and SWIFT‑2) that...
Study Hints at Clinical Lab’s Future Role in Investigating Sudden Unexplained Death in Children
UW Medicine and Seattle Children’s Hospital received $328,133 from the Sudden Unexplained Death in Childhood (SUDC) Foundation to launch a four‑year study using PacBio HiFi long‑read sequencing as a first‑line test. The project will sequence 200 child‑parent trios to uncover...
Podcast: Rare Disease Day: FDA Guidance Allowing Advancement
The FDA issued a suite of new guidance documents in early 2026 aimed at easing development of therapies for rare diseases, including the Rare Disease Evidence Pathway, Plausible Mechanism Pathway, and innovative trial designs for cellular and gene therapies. The...
Charge‐Tuning Ice Inhibition in Antifreeze Peptides
Researchers engineered a series of antifreeze peptides (AFPTs) with systematically varied charges on their non‑ice‑binding sites (NIBSs) to uncover how charge influences ice‑growth inhibition. They found that moderate net‑negative charges improve peptide adsorption onto ice via hydration‑mediated interfaces, while excessive...
Quotient and Ipsen Extend Partnership for Ultra-Rare Disease Therapy
Quotient Sciences has extended its commercial partnership with Ipsen to manufacture Sohonos (Palovarotene), the approved therapy for fibrodysplasia ossificans progressiva (FOP), an ultra‑rare disease affecting fewer than 1,000 people worldwide. The deal includes Ipsen's investment in a pneumatic closed‑transfer system...
ENDRA Reports Favourable Data From Taeus Liver Device Study in MASLD
ENDRA Life Sciences announced that its Taeus Liver device achieved high measurement consistency in a MASLD study, recording an intraclass correlation coefficient of 0.89 and a standard error of measurement of 3.3%. The trial involved 14 participants and 56 data...
Bayer Reports P-III (PEACE-3) Trial Data on Xofigo Combination for Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases
Bayer announced that its phase‑III PEACE‑3 trial demonstrated a statistically significant overall‑survival benefit for the combination of Xofigo (radium‑223) and enzalutamide versus enzalutamide alone in patients with metastatic castration‑resistant prostate cancer (mCRPC) and bone metastases. Median overall survival extended to...
National Taiwan University Hospital Develops AI for Pancreatic Cancer Metabolic Profiling
Taiwan’s Academia Sinica and National Taiwan University Hospital have launched PanMETAI, an AI‑integrated metabolomics platform that analyzes roughly 260,000 metabolic signals from a 500‑microliter blood‑serum sample. Using deep‑learning on nuclear magnetic resonance data, the model achieved a 99% area‑under‑curve for distinguishing...
Mutant P53 Selective Reactivation Demonstrated in Advanced Solid Tumors
PMV Pharmaceuticals reported Phase I results of rezatapopt, a small‑molecule p53 reactivator, in 77 patients with advanced solid tumors carrying the TP53 Y220C mutation. The oral drug was generally well tolerated, with few dose‑limiting toxicities, allowing the selection of a...
Fulgent Genetics Inc (FLGT) Q4 2025 Earnings Call Transcript
Fulgent Genetics reported Q4 2025 revenue of $84.1 million, a sequential increase and strong year‑over‑year growth across its Precision Diagnostics and Biopharma segments. Non‑GAAP gross margin improved to 44.3% while operating expenses fell, delivering a $0.7 million adjusted EBITDA and a $4.5 million...
Editorial Expression of Concern: The Gene Product Murr1 Restricts HIV-1 Replication in Resting CD4+ Lymphocytes
An expression of concern has been issued for a 2003 Nature paper that reported the gene product Murr1 restricts HIV‑1 replication in resting CD4⁺ lymphocytes. The editors identified duplicated control panels in Figure 3b, which were meant to demonstrate siRNA activity,...
Johnson Floats ‘Right To Try 2.0’ As Makary Defends FDA’s Approval Standards
Senator Ron Johnson (R‑WI) is urging Congress to draft a “Right to Try 2.0” bill that would force the FDA to grant broader, faster access to experimental therapies for rare diseases. FDA Commissioner Martin Makary pushed back, defending the agency’s...
Catalyst OrthoScience Gets FDA 510(k) Clearance of Archer® Patient-Specific Instrumentation for Shoulder Arthroplasty
Catalyst OrthoScience announced FDA 510(k) clearance for its Archer® Patient‑Specific Instrumentation (PSI), a suite of humeral and glenoid guides designed to translate 3D pre‑operative plans into the operating room. The system pairs with Archer® 3D Planning Software, supporting both anatomic...
Exploring Lymphovenous Bypass as a Promising Surgical Approach for Alzheimer’s Disease
Researchers have adapted lymphovenous bypass, a microsurgical technique that reroutes lymphatic fluid into the venous system, as a potential treatment for Alzheimer’s disease. In a Phase I pilot study of 20 patients, the procedure reduced cerebral amyloid‑β levels by roughly 30%...
Single-Cell Study Links Hair Loss to Tissue Contraction
A 2026 Nature Communications study used single‑cell RNA sequencing to map the hair follicle microenvironment in men with androgenetic alopecia. The researchers discovered that fibroblasts in the connective tissue sheath (CTS) adopt an abnormal actomyosin‑driven contractile phenotype, compressing follicles and...
Targeted PET/CT Tracer Helps Rheumatoid Arthritis Patients
A new macrophage‑targeted PET/CT tracer (11C‑DPA‑713) can identify rheumatoid arthritis patients who will respond to anti‑TNF therapy within four weeks, far earlier than the traditional three‑to‑six‑month window. The study of 20 patients showed that standardized uptake values (SUVs) at baseline...
FDA Grants Accelerated Approval to Zongertinib for HER2-Mutant NSCLC
The FDA granted accelerated approval to zongertinib (Hernexeos) for adults with unresectable or metastatic non‑squamous NSCLC that carry activating HER2 TKD mutations, extending its use to treatment‑naive patients. The decision rests on the Beamion LUNG‑1 trial, which reported a 76%...
Increasing Rice Yields with Gene-Informed Selective Breeding
An international team led by Oxford, Nanjing Agricultural University and the Chinese Academy of Sciences identified the rice gene OsWRI1a as a key regulator of growth under varying nitrogen levels. Over‑expressing a strong OsWRI1a allele increased root‑to‑shoot ratios and grain...
How RNA Binding Selectivity Arises From Disordered Regions
RIKEN scientists have shown that an intrinsically disordered region (IDR) of the DEAD‑box helicase DDX3X confers selective binding to specific mRNA structures, a mechanism uncovered using solution NMR spectroscopy. The discovery clarifies how DDX3X distinguishes target transcripts, linking its specificity...
ARUP Creates Innovation Central Laboratory
ARUP Laboratories has unveiled the Innovation Central Laboratory, a dedicated hub for co‑development with pharmaceutical and biotech partners. The facility is designed to validate technologies and move next‑generation diagnostics from concept through to commercial readiness. It will host projects ranging...
Drug Trials Snapshots: KOMZIFTI
The FDA approved KOMZIFTI (ziftomenib) on November 13 2025 as an oral 600 mg capsule for adult patients with relapsed or refractory acute myeloid leukemia (AML) harboring an NPM1 mutation. Approval rests on the single‑arm KO‑MEN‑001 trial, which enrolled 112 participants across seven...
This Biomaterial Becomes Stronger when Wet
Researchers at the Institute for Bioengineering of Catalonia have created a nickel‑linked chitosan material that becomes stronger when wet, achieving nearly a 50 % increase in tensile strength. By incorporating small amounts of nickel ions, the polymer forms water‑bridged networks that...
U of T Taps BioLabs to Take over Incubator After Johnson & Johnson Pulls Support
The University of Toronto has partnered with Cambridge‑based BioLabs to operate its 40,000‑square‑foot life‑sciences incubator after Johnson & Johnson announced it will withdraw support by the end of 2025. BioLabs, entering Canada for the first time, will manage the space...
BIO Patient Advocacy Coffee Chat: Act Now to Be Heard on CMS Drug Pricing
The Centers for Medicare & Medicaid Services entered the third year of its Medicare drug price negotiation program, selecting 15 drugs—including, for the first time, therapies covered under Medicare Part B. Patient advocacy groups have until March 1 to submit written comments...
Reusable MoS₂ RF Biosensor Enables Cost-Effective Liquid Biopsies for Early Cancer Detection
Researchers at UNIST, KAIST and Yonsei have developed a reusable molybdenum disulfide (MoS₂) radio‑frequency biosensor for liquid‑biopsy cancer detection. The sensor detects single‑stranded DNA fragments as low as 154.67 nM by monitoring shifts in resonant frequency, and can be washed and...
Bristol Myers Says ADC Licensed From China Hits Mark in Aggressive Breast Cancer
Bristol Myers Squibb reported that its antibody‑drug conjugate iza‑bren, licensed from Chinese partner SystImmune, achieved statistically significant improvements in progression‑free and overall survival versus chemotherapy in a Phase III trial for advanced triple‑negative breast cancer. The study, conducted in mainland China...
After Sarepta’s Annus Horribilis, Elevidys Sales Expected To Continue Downward Spiral
Elevidys, Sarepta Therapeutics’ gene therapy for Duchenne muscular dystrophy, posted $110 million in fourth‑quarter sales, bringing full‑year revenue to $898.7 million—well below the $1 billion benchmark. Safety incidents in 2025 and a severe flu season have eroded confidence, prompting analysts to project 2026...
![[Comment] Impact of Adding Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/f1452ec53e5201a4460c9aaf141538d3.webp)
[Comment] Impact of Adding Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer
Adding androgen deprivation therapy (ADT) to definitive radiotherapy improves overall survival for men with high‑risk prostate cancer, but its benefit when combined with postoperative radiotherapy (PORT) after prostatectomy is less clear. Randomised trials such as GETUG‑AFU 16, SPPORT, and the RADICALS‑HD...
FDA’s One Trial Policy Not a Revolution but a Potentially Risky Evolution
The FDA announced it will default to a single pivotal trial for new drug applications, extending a practice long used in oncology and rare‑disease approvals. In 2024, 66% of new molecular entities were cleared based on one trial, signaling a...
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
The latest episode of BioSpace’s Denatured podcast spotlights a growing partnership between ALS patients and pharmaceutical developers, featuring insights from EverythingALS founder Indu Navar and VectorY Therapeutics CMO Dr. Olga Uspenskaya. The discussion highlights how patient‑driven collaborations are accelerating trial timelines...
Government Panel Said to Review Future of Key GM Food Crop
India’s ministerial panel will examine field trials of a genetically modified rapeseed (mustard) variety, a step that could reshape the country’s cautious stance on GM food crops. The review comes as the Supreme Court prepares to revisit a pending case...
STAT+: FDA Rejection Is a Reality Check on Agency Rhetoric
The U.S. Food and Drug Administration rejected a rare‑disease cell therapy that had already secured approval in Europe, despite earlier internal support from the agency. The decision comes under the FDA’s new leadership and has sparked debate over whether the...
